FocalTherics (NASDAQ:FOCL) CFO Kenneth Mobeck Acquires 5,000 Shares of Stock

FocalTherics (NASDAQ:FOCL) CFO Kenneth Mobeck acquired 5,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, with a total value of $23,750.00. Following the completion of the purchase, the chief financial officer directly owned 181,610 shares of the company’s stock, valued at $862,647.50. This trade represents a 2.83% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

FocalTherics Trading Down 8.4%

Shares of FOCL opened at $4.36 on Tuesday. FocalTherics has a twelve month low of $1.30 and a twelve month high of $6.40. The stock has a market capitalization of $163.41 million, a P/E ratio of -4.23 and a beta of -0.04. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The company has a fifty day moving average price of $5.38.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The firm had revenue of $13.20 million during the quarter. Analysts predict that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FocalTherics

Large investors have recently added to or reduced their stakes in the stock. Rock Springs Capital Management LP grew its stake in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after acquiring an additional 91,500 shares in the last quarter. Flax Pond Capital LLC bought a new stake in shares of FocalTherics during the fourth quarter valued at approximately $2,623,000. Leonteq Securities AG bought a new stake in shares of FocalTherics during the fourth quarter valued at approximately $313,000. Kovack Advisors Inc. purchased a new stake in shares of FocalTherics in the fourth quarter valued at approximately $53,000. Finally, Lido Advisors LLC purchased a new stake in shares of FocalTherics in the first quarter valued at approximately $40,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on FOCL. Mizuho set a $15.00 target price on FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $7.75.

More FocalTherics News

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
• Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
• Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.